These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 7602087)

  • 1. Prospects for hepatitis C vaccine.
    Zuckerman AJ; Zuckerman JN
    J Hepatol; 1995; 22(1 Suppl):97-100. PubMed ID: 7602087
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of a heterologous, multigenotype vaccine against hepatitis C virus infection.
    Encke J; Radunz W; Eisenbach C; Geib J; Gehrke S; Pfaff E; Stremmel W
    Eur J Clin Invest; 2007 May; 37(5):396-406. PubMed ID: 17461986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospects for a vaccine against the hepatitis C virus.
    Houghton M; Abrignani S
    Nature; 2005 Aug; 436(7053):961-6. PubMed ID: 16107836
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unscrambling hepatitis C virus-host interactions.
    Chisari FV
    Nature; 2005 Aug; 436(7053):930-2. PubMed ID: 16107831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel combined vaccine candidate containing epitopes of HCV NS3, core and E1 proteins induces multi-specific immune responses in BALB/c mice.
    Zeng R; Li G; Ling S; Zhang H; Yao Z; Xiu B; He F; Huang R; Wei L
    Antiviral Res; 2009 Oct; 84(1):23-30. PubMed ID: 19646486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Hepatitis C virus vaccine].
    Wakita T
    Nihon Rinsho; 2008 Oct; 66(10):1961-4. PubMed ID: 18939497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Selection of antigenic and immunogenic mimics of hepatitis C virus using sera from patients.
    Prezzi C; Nuzzo M; Meola A; Delmastro P; Galfrè G; Cortese R; Nicosia A; Monaci P
    J Immunol; 1996 Jun; 156(11):4504-13. PubMed ID: 8666827
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cutting the gordian knot-development and biological relevance of hepatitis C virus cell culture systems.
    Gottwein JM; Bukh J
    Adv Virus Res; 2008; 71():51-133. PubMed ID: 18585527
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel hepatitis C virus vaccine approach using recombinant Bacillus Calmette-Guerin expressing multi-epitope antigen.
    Wei SH; Yin W; An QX; Lei YF; Hu XB; Yang J; Lu X; Zhang H; Xu ZK
    Arch Virol; 2008; 153(6):1021-9. PubMed ID: 18421415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nucleic acid vaccines against hepatitis viruses.
    Howard CR; Gray L; D'Mello F; Christopher J; Craske J
    Dev Biol Stand; 1998; 92():157-62. PubMed ID: 9554270
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis C and its sequelae: the biology of hepatitis C virus and implications for its control.
    Purcell RH
    Princess Takamatsu Symp; 1995; 25():1-13. PubMed ID: 8875604
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular methods of hepatitis C genotyping.
    Weck K
    Expert Rev Mol Diagn; 2005 Jul; 5(4):507-20. PubMed ID: 16013969
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Virology of hepatitis C virus].
    Hofmann H
    Wien Med Wochenschr; 2000; 150(23-24):463-6. PubMed ID: 11205175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment and vaccination for hepatitis C: present and future.
    Jawaid A; Khuwaja AK
    J Ayub Med Coll Abbottabad; 2008; 20(1):129-33. PubMed ID: 19024206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in hepatitis C virus vaccines, Part one: Advances in basic knowledge for hepatitis C virus vaccine design.
    Roohvand F; Kossari N
    Expert Opin Ther Pat; 2011 Dec; 21(12):1811-30. PubMed ID: 22022980
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Codon optimization and mRNA amplification effectively enhances the immunogenicity of the hepatitis C virus nonstructural 3/4A gene.
    Frelin L; Ahlén G; Alheim M; Weiland O; Barnfield C; Liljeström P; Sällberg M
    Gene Ther; 2004 Mar; 11(6):522-33. PubMed ID: 14999224
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of prophylactic and therapeutic vaccines against hepatitis C virus.
    Leroux-Roels G
    Expert Rev Vaccines; 2005 Jun; 4(3):351-71. PubMed ID: 16026249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protective vaccination with hepatitis C virus NS3 but not core antigen in a novel mouse challenge model.
    El-Gogo S; Staib C; Lasarte JJ; Sutter G; Adler H
    J Gene Med; 2008 Feb; 10(2):177-86. PubMed ID: 18076128
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Hepatitis C virus].
    Querenghi F; Zoulim F
    Rev Prat; 2000 May; 50(10):1060-5. PubMed ID: 10905089
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Absence of extensive genetic heterogeneity of hepatitis C virus in antibody-negative chronic hepatitis C.
    Kao JH; Chen PJ; Yang PM; Lai MY; Wang TH; Chen DS
    J Med Virol; 1996 Jun; 49(2):87-90. PubMed ID: 8991941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.